We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.
- Authors
Oziel-Taieb, Sandrine; Maniry-Quellier, Jemima; Chanez, Brice; Poizat, Flora; Ewald, Jacques; Niccoli, Patricia
- Abstract
Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypoglycemia. After several ineffective locoregional and systemic therapeutic lines for the secretory disease, the introduction of pasireotide, a second-generation somatostatin analog, provided an improved clinical and secretory evolution both quickly and sustainably, with an excellent safety profile. Pasireotide is an effective and well-tolerated therapy in the treatment of refractory hypoglycemia in metastatic insulinoma.
- Subjects
HYPOGLYCEMIA; INSULINOMA; NEUROENDOCRINE tumors; LITERATURE reviews; PANCREATIC tumors; SOMATOSTATIN
- Publication
Frontiers in Endocrinology, 2022, Vol 13, p1
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2022.860614